`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`MYLAN INSTITUTIONAL LLC,
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2020-00324
`Patent 8,114,833
`______________
`
`
`PATENT OWNER’S NOTICE OF SUPPLEMENTAL EVIDENCE IN
`RESPONSE TO PETITIONER’S OBJECTIONS TO EXHIBITS
`
`
`
`
`
`
`
`
`IPR2020-00324
`Patent 8,114,833
`Patent Owner Novo Nordisk A/S (“Novo Nordisk”) submits this Notice of
`
`
`
`Supplemental Evidence in Response to Petitioner Mylan Institutional LLC’s
`
`(“Mylan”) Objections to Patent Owner’s Evidence dated September 25, 2020. In
`
`response to Mylan’s objections, Novo Nordisk serves herewith supplemental
`
`evidence, identified as Exhibits 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090,
`
`2091, 2092, 2093, and 2094 pursuant to 37 C.F.R. § 42.64(b)(2). Novo Nordisk
`
`further serves herewith its Amended List of Exhibits pursuant to 37 C.F.R. §
`
`42.63(e), identifying its supplemental evidence.
`
`Mylan objected to Exhibit Nos. 2051, 2052, 2053, 2055, 2057, 2058, 2059,
`
`2060, 2062, 2063, 2065, and 2069 (collectively, the “Translated Exhibits”) under 37
`
`C.F.R. § 42.63(b) as “failing to file an affidavit.” The only context for its objection
`
`that Mylan provided was: “the translation filed with the underlying document is not
`
`filed with an affidavit in accordance with 37 C.F.R. § 42.63(b).” Paper 23 at 11.
`
`37 C.F.R. 42.63(b) states: “When a party relies on a document or is required
`
`to produce a document in a language other than English, a translation of the
`
`document into English and an affidavit attesting to the accuracy of the translation
`
`must be filed with the document.”
`
`The Translated Exhibits did include affidavits attesting to the accuracy of the
`
`translation, along with the original Danish language document and certified English
`
`translation thereof. Mylan has not explained its position as to why the original
`
`
`
`1
`
`
`
`IPR2020-00324
`Patent 8,114,833
`affidavits were allegedly not in accordance with 37 C.F.R. § 42.63(b). Mylan’s
`
`
`
`objection therefore does not “identify the grounds for the objection with sufficient
`
`particularity to allow correction in the form of supplemental evidence,” as is required
`
`under 37 C.F.R. § 42.64(b)(1).
`
`Nevertheless, in an effort to resolve Mylan’s objections under 37 C.F.R. §
`
`42.63(b)(1), Novo Nordisk serves herewith as supplemental evidence a copy of each
`
`Translated Exhibit, which includes a supplemental affidavit. Inclusion of the
`
`supplemental affidavit with each Translated Exhibit should resolve Mylan’s
`
`objections under 37 C.F.R. § 42.63(b)(1), despite Mylan’s failure to clearly articulate
`
`the grounds for its objections.
`
`Novo Nordisk reserves all rights to respond to any further explanations Mylan
`
`may be allowed to provide regarding its evidentiary objections. Novo Nordisk’s
`
`service of supplemental evidence is timely under 37 C.F.R. § 42.64(b)(2) because it
`
`is served within 10 business days of the service of Mylan’s objections.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`-2-
`
`
`
`
`Dated: October 9, 2020
`
`
`
`
`
`
`
`
`
`
`
`IPR2020-00324
`Patent 8,114,833
`
`Respectfully submitted,
`
`/s/ Jeffrey J. Oelke (Electronically signed)
`Jeffrey J. Oelke, Reg. No. 37,409
`Lead Counsel
`
`Ryan P. Johnson
`Laura T. Moran
`Back-Up Counsel
`
`Fenwick & West LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600
`joelke@fenwick.com
`ryan.johnson@fenwick.com
`laura.moran@fenwick.com
`
`Counsel for Patent Owner Novo Nordisk A/S
`
`
`
`-3-
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2020-00324
`Patent 8,114,833
`
`Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on October 9, 2020, the
`
`foregoing document is being served by filing this document through the Patent Trial and
`
`Appeal Board End to End System, as well as by delivering a copy via electronic mail
`
`upon the following counsel of record for the Petitioner:
`
`Brandon M. White (Reg. No. 52,354)
`Perkins Coie LLP
`700 Thirteenth Street, N.W., Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`BMWhite@perkinscoie.com
`White-ptab@perkinscoie.com
`
`Lara Dueppen (Reg. No. 65,002)
`Perkins Coie LLP
`1888 Century Park East
`Suite 1700
`Los Angeles, CA 90067
`Telephone: (310) 788-3349
`LDueppen@perkinscoie.com
`Dueppen-ptab@perkinscoie.com
`Liraglutide@perkinscoie.com
`
`
`
`
`
`
`Respectfully submitted,
`
`/s/ Jeffrey J. Oelke (Electronically signed)
`Jeffrey J. Oelke, Reg. No. 37,409
`Lead Counsel
`
`-4-
`
`
`
`
`
`
`
`
`
`Date: October 9, 2020
`
`
`